Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC). Preclinically, HER3 ligand heregulin induces resistance to EGFR-TKIs, whereas the pan-human EGFR family inhibitor afatinib remains effective. Here, we exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonesaka, Kimio, Iwama, Eiji, Hayashi, Hidetoshi, Suzuki, Shinichiro, Kato, Ryoji, Watanabe, Satomi, Takahama, Takayuki, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Sakai, Kazuko, Azuma, Koichi, Chiba, Yasutaka, Atagi, Shinji, Nishio, Kazuto, Okamoto, Isamu, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925200/
https://www.ncbi.nlm.nih.gov/pubmed/31862929
http://dx.doi.org/10.1038/s41598-019-55939-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925200/
https://www.ncbi.nlm.nih.gov/pubmed/31862929
http://dx.doi.org/10.1038/s41598-019-55939-5

Ejemplares similares